Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Aurinia Pharmaceuticals Inc (AUPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AUPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 19.06% | Avg. Invested days 49 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.11B USD | Price to earnings Ratio 201.25 | 1Y Target Price 9.83 |
Price to earnings Ratio 201.25 | 1Y Target Price 9.83 | ||
Volume (30-day avg) 1629191 | Beta 1.27 | 52 Weeks Range 4.71 - 10.67 | Updated Date 04/2/2025 |
52 Weeks Range 4.71 - 10.67 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.45% | Operating Margin (TTM) 13% |
Management Effectiveness
Return on Assets (TTM) 1.42% | Return on Equity (TTM) 1.52% |
Valuation
Trailing PE 201.25 | Forward PE 16.37 | Enterprise Value 826472078 | Price to Sales(TTM) 4.7 |
Enterprise Value 826472078 | Price to Sales(TTM) 4.7 | ||
Enterprise Value to Revenue 3.51 | Enterprise Value to EBITDA 26.05 | Shares Outstanding 137339008 | Shares Floating 133424854 |
Shares Outstanding 137339008 | Shares Floating 133424854 | ||
Percent Insiders 7.48 | Percent Institutions 45.2 |
Analyst Ratings
Rating 4.29 | Target Price 10.84 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aurinia Pharmaceuticals Inc
Company Overview
History and Background
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies to treat autoimmune diseases. Founded in 2003, it gained prominence with the development of LUPKYNIS for lupus nephritis.
Core Business Areas
- Pharmaceutical Development and Commercialization: Focuses on discovering, developing, and commercializing therapies for autoimmune diseases, with LUPKYNIS being their primary product.
Leadership and Structure
The leadership team includes key executives in areas such as CEO, CFO, and Chief Medical Officer. The company is structured with departments focused on research, development, commercialization, and administration.
Top Products and Market Share
Key Offerings
- LUPKYNIS (voclosporin): LUPKYNIS is an oral medication approved for the treatment of adult patients with active lupus nephritis (LN) in combination with a background immunosuppressive regimen. Competitors include conventional immunosuppressants like mycophenolate mofetil and cyclophosphamide, and biologics such as Benlysta (belimumab). Market share data is difficult to pinpoint exactly due to changing market dynamics and lack of precise disclosures, but it has been estimated to be below 25% within its specific niche. Revenue estimates varies by analyst firms.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the segment focused on autoimmune diseases, is characterized by high research and development costs, stringent regulatory requirements, and intense competition.
Positioning
Aurinia Pharmaceuticals Inc. is positioned as a specialist in lupus nephritis treatment with LUPKYNIS, aiming to capture a significant share of the LN market.
Total Addressable Market (TAM)
The TAM for lupus nephritis treatment is estimated to be in the billions of dollars. Aurinia, with LUPKYNIS, is attempting to capture a significant portion of this TAM. Specific TAM estimate depends on analysts research, but it is estimated between 3 Billion to 5 Billion.
Upturn SWOT Analysis
Strengths
- Approved and marketed product (LUPKYNIS)
- Focus on a specific disease (lupus nephritis)
- Strong IP protection for LUPKYNIS
Weaknesses
- Reliance on a single product
- Relatively small company size
- Market acceptance and adoption of new drug
- High marketing and commercialization costs
Opportunities
- Expanding LUPKYNIS' market reach to other geographies
- Developing new indications for voclosporin
- Potential for partnerships or acquisitions
- Advancements in autoimmune disease research
Threats
- Competition from existing and new therapies
- Regulatory changes affecting drug approvals
- Pricing pressures and reimbursement challenges
- Patent expiration
Competitors and Market Share
Key Competitors
- BMY
- GSK
- HLN
- AMGN
Competitive Landscape
Aurinia's advantage lies in LUPKYNIS's specific approval for lupus nephritis. Disadvantages include being a smaller company with fewer resources compared to larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the launch and sales ramp-up of LUPKYNIS.
Future Projections: Future growth is projected to be driven by continued adoption of LUPKYNIS, potential expansion into new markets, and possible pipeline developments. Analyst estimates depend on their firms research reports.
Recent Initiatives: Recent initiatives include expanding the sales force, conducting clinical trials to evaluate LUPKYNIS in other indications, and forging partnerships to expand market reach.
Summary
Aurinia Pharmaceuticals is focused on autoimmune diseases, primarily lupus nephritis. LUPKYNIS is its key product, approved for LN. While Aurinia has strengths in its niche, it faces competition from larger companies and relies heavily on a single product. Growth depends on LUPKYNIS's market adoption and possible pipeline expansion, but it must be mindful of financial management for future growth.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GSK
GlaxoSmithKline PLC ADR
GSK
GlaxoSmithKline PLC ADR
HLN
Haleon plc
HLN
Haleon plc
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
- Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aurinia Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Edmonton, AB, Canada | ||
IPO Launch date 1999-01-26 | CEO & Director Mr. Peter S. Greenleaf M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://www.auriniapharma.com |
Full time employees 130 | Website https://www.auriniapharma.com | ||
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.